Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Curie Therapeutics has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in December 2021.
Curie Therapeutics's investors include RA Capital Management, Atlas Venture, Access Biotechnology.
Curie Therapeutics is headquartered in Boston, United States.
Curie Therapeutics is a fully integrated next-generation radiopharmaceutical firm that combines ligand research and radiochemistry experts.
Curie Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Curie Therapeutics — Funding & Investors." VCBacked, December 1, 2021, https://www.vcbacked.co/company/curie-therapeutics. Accessed October 1, 2026.
VCBacked. (2021). Curie Therapeutics — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/curie-therapeutics
{{cite web |title=Curie Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/curie-therapeutics |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated